Project Details
Description
The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is used to treat people with Hemophilia A in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians are with the treatment.
| Acronym | HEM-POWR |
|---|---|
| Status | Active |
| Effective start/end date | 21/10/19 → 31/03/27 |
Collaborative partners
- Ministry of Health and Prevention
- Bayer (lead)
Keywords
- Inherited Blood Coagulation Disorders
- Blood Coagulation Disorders
- Hematologic Diseases
- Coagulation Protein Disorders
- Hemorrhagic Disorders
- Inborn Genetic Diseases
- Hemophilia A
- Coagulants
- Factor VIII
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.